FAQs About Stem Cell Method & Erectile Dysfunction Treatment

Most standard ED treatments are medication-based and symptom-focused (such as Viagra or Levitra). They may help trigger an erection temporarily but do not address the underlying nerve or vascular damage that causes erectile dysfunction. PDE5 inhibitors are effective in only about 50% of men after radical prostatectomy.

Yes. The protocol is based on peer-reviewed Danish clinical research, including published clinical trials in The Lancet’s eBioMedicine and The Journal of Urology focused on men with severe erectile dysfunction after prostate cancer surgery.

The study showed that 73% of urine-continent patients went from complete loss of erectile function to full erectile recovery.

This group was chosen because it is one of the hardest ED populations to treat, making it a rigorous proof point. Regenerative medicine is an evolving field, but this protocol is grounded in published clinical trial data – not theory or marketing claims.

Regenerative means supporting the body’s ability to repair itself, rather than forcing a short-term response. In erectile dysfunction, this means focusing on the nerves and blood vessels involved in erections. When those structures are damaged, pharmaceutical treatments like Viagra may be insufficient. Regenerative approaches aim to restore tissue function so the body can do more of the work on its own.

The treatment uses your own cells. It is based on adipose-derived stem cells collected from approximately 400 ml of fat tissue from the abdomen or thighs. The relevant cells are prepared and used on the same day. No donor cells are involved.

Using your own cells reduces immune risk and is a key reason this approach has a strong safety profile when performed correctly.

In many countries, including the United States, regenerative cell treatments for erectile dysfunction are not widely available as standard care, despite demonstrated effectiveness in several medical fields. This is largely due to regulatory frameworks rather than a lack of scientific basis.

For example, stem cell treatments are standard care for conditions such as childhood leukemia and bone marrow transplantation, including in the U.S. The science itself is well established. What remains limited is access to effective ED-specific applications using a patient’s own cells. We are careful to distinguish between what is well established and what is still under study.

The original human study behind this protocol was designed to assess safety. The injection procedure was well tolerated, and no serious adverse events related to the cell treatment were reported.

The main medical consideration for the treatment is the fat-harvesting step, which involves a standard small 400 ml liposuction and this is why a hospital-grade setting is essential.

 Patient screening is critical, and we do not treat patients with active cancer or certain serious cardiac conditions.

Results depend on the cause and severity of your erectile dysfunction, your overall health, and how long the condition has been present.

Published data comes from men with erectile dysfunction after prostate cancer surgery. In that clinical study, 73% of continent patients experienced full functional recovery, despite having zero erectile function at baseline.

However, outcomes are significantly less favorable if a patient has (1) fibrosis in the penile tissue, (2) incontinence, or (3) has had no erectile function for more than three years, with or without medication. Not everyone responds, and our screening process is designed to be honest about whether this treatment is a reasonable option.

The results are intended to be permanent. The regenerative process typically takes four to six months, as the stem cells work to regenerate damaged nerves and form new blood vessels.

The treatment includes three follow-up consultations at months 6, 9, and 12. Progress is evaluated using the internationally recognized IIEF-5 erectile function score and a nocturnal erection monitoring device provided for home use.

Because regenerative responses vary between individuals, durability can differ. This is why follow-up and outcome tracking are emphasized.

Men with active cancer, uncontrolled medical conditions, serious bleeding disorders, or infections that increase surgical risk are generally not candidates. Men with primarily psychological ED or medication-induced ED may also not benefit. Patients with penile fibrosis or incontinence typically have lower chances of success.

Screening is designed to protect patients and avoid unrealistic expectations. Being advised against treatment is sometimes the safest and most responsible outcome.

Because it represents the toughest test case. Demonstrating recovery in men with severe post-surgical ED provides strong evidence that the underlying regenerative mechanism is real. This makes prostate cancer patients a meaningful proof point rather than an easy win and reflects the seriousness of the original research program.

Most men are advised to allow time for natural recovery and standard rehabilitation first. Regenerative options are typically considered several months after surgery, once healing has stabilized. Timing depends on nerve-sparing status, continence, and overall recovery and is assessed individually during screening.

Not always, but often. Some men gradually regain function with conventional treatments, but many experience severe or complete erectile dysfunction after radical prostatectomy.

The goal of this treatment is to support recovery where biological potential still exists, and in some cases to restore function even after complete loss, consistent with the clinical trial data in which all participating patients had complete erectile dysfunction following surgery.

Penile rehabilitation focuses on preserving tissue health through medications, injections, devices, and time. These programs can be helpful, especially early after surgery.

The Nordic Method targets tissue repair itself, particularly nerves and blood vessels. It is not a replacement for rehabilitation, but a different category of treatment that may be considered when standard rehabilitation has not produced results.

The Nordic Method was developed for prostate cancer patients, but it may also help some men with diabetes-related ED, depending on the extent of damage and overall health. Regenerative approaches aim to support vascular and tissue health, which is relevant in diabetic ED. However, diabetes-related ED varies widely, and outcomes are less predictable. We currently do not have clinical trial data specific to diabetic ED, making careful screening essential.

Yes, most likely. Prostate cancer surgery causes a specific injury at a specific time, while diabetes causes ongoing systemic damage. This can make outcomes more variable. Improvement may still be possible, but expectations must be individualized.

This is not about enhancement or optimization for its own sake. The focus is on clinically meaningful erectile dysfunction with a physical cause. While the regenerative process involves formation of new nerves and blood vessels and may theoretically rejuvenate penile tissue, we do not yet have clinical trial data to support claims related to age-related ED. Dedicated trials are planned to address this.

There is no strict age cutoff. Overall health, cardiovascular status, and suitability for a minor surgical procedure matter more than age itself. Patients are evaluated based on medical fitness, with safety as the primary consideration.

Some use that term, but it does not fully describe the situation. Patients travel for a specific medical protocol delivered in a clinical environment with hospital support. This is not a wellness retreat or vacation-based treatment. It is better described as cross-border medical care.

We operate with a conservative medical approach that emphasizes screening, sterile laboratory techniques, clinical trial documentation, and structured follow-up. The surgical procedure is performed in at CIMA hospital and the stem cell injection at our newly build clinic in the CIMA hospital compounds. This level of structure is intentional and central to patient safety.

The clinic is located in Avenida Médica in San José within the CIMA Hospital compound. The fat-harvesting liposuction is performed at CIMA Hospital by an experienced surgeon in a hospital-grade setting. The injection step takes place at our clinic within the same medical complex at our new lybuild clinic.

The hospital is used for the surgical step that requires the highest safety standards, including sterile conditions, monitoring, and specialized staff. This adds an important layer of safety and credibility.

Travel requires planning, but medical risk is minimized through careful screening and clear recovery guidelines. Most patients are able to travel safely with standard precautions. We will advise against treatment if a patient’s health profile makes travel unsafe.

Mini-liposuction is widely used but carries low risks such as soreness, bruising, swelling, infection, or bleeding. Serious complications are uncommon but possible. This is why the procedure is performed in a hospital-grade environment and why patient selection is critical.

We provide guidance on recovery, expected timelines, and follow-up communication. Because regenerative changes take time, ongoing monitoring is important. Many patients also keep their local physician informed. We encourage coordinated care rather than isolation.

The protocol is designed as a single treatment session using your own cells. Unlike recurring injections or medication-based approaches, the goal is to stimulate a regenerative response rather than provide repeated short-term effects.

The cells are processed and administered on the same day. No long-term storage or banking is involved in this protocol.

Pre-treatment evaluation typically includes a detailed medical history, cardiovascular screening, laboratory work, and assessment of erectile function. Additional testing may be required depending on age, health status, and risk factors.

The primary goal is functional recovery in men with clinically significant erectile dysfunction caused by identifiable physical factors. The extent of improvement varies, and outcomes cannot be guaranteed. Screening helps define realistic expectations.